Zika virus vaccine - Themis Bioscience

Drug Profile

Zika virus vaccine - Themis Bioscience

Alternative Names: MV-ZIKA; MV-Zika vaccine

Latest Information Update: 13 Apr 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Themis Bioscience
  • Class Zika virus vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Phase I Zika virus infection

Most Recent Events

  • 04 Apr 2017 Phase-I clinical trials in Zika virus infection (In volunteers) in Austria (Parenteral) (EudraCT2016-004212-34)
  • 16 Dec 2016 Themis Bioscience plans a phase I trial for Zika virus infections (In volunteers) in Austria (NCT02996890)
  • 13 Dec 2016 Preclinical trials in Zika virus infection in Austria (Parenteral) before December 2016 (NCT02996890)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top